文献速递白血病造血干细胞移植与细胞治疗

酪氨酸激酶抑制剂时代费城染色体阳性急性淋巴细胞白血病首次复发结局

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
PubMed 文献 · Am J Hematol · 2019-10-21

该研究回顾性分析233例接受hyperCVAD联合TKI一线治疗的成人Ph+ ALL患者,57例(25%)首次形态学复发,中位复发时间15.9个月。挽救治疗后第二次缓解率84%,中位无复发生存10.5个月,1年和2年总生存率分别为41%和20%。多因素分析显示LDH升高、首次复发时使用第一代TKI或无TKI、未达主要分子学缓解影响总生存,仅主要分子学缓解与无复发生存显著相关。

要点

  • Ph+ ALL首次复发后第二次缓解率84%,但长期生存仍有限。
  • 首次复发时使用第一代TKI或无TKI与更差总生存相关。
  • 达到主要分子学缓解是改善无复发生存的关键预后因素。

核心结论

  • Ph+ ALL首次形态学复发后挽救治疗可获得较高二次缓解率,但长期生存仍不理想。
  • 首次复发时使用第一代TKI或无TKI、LDH升高与更差总生存相关,达到主要分子学缓解与更好生存相关。

研究设计与样本

  • 回顾性队列研究,纳入233例接受一线hyperCVAD联合TKI治疗的成人Ph+ ALL患者。
  • 57例(25%)发生首次形态学复发,中位复发时间15.9个月(范围5.3-94)。

主要发现

  • 43例(75%)复发患者接受TKI联合挽救治疗,49例可评估患者中41例(84%)达到第二次缓解。
  • 中位无复发生存10.5个月(范围0.2-81),1年和2年总生存率分别为41%和20%。
  • 第二次缓解后接受与未接受异基因造血干细胞移植的患者总生存和无复发生存相当,移植组非复发死亡率为53%。

临床怎么用

  • Ph+ ALL首次复发时应优先考虑包含TKI的挽救方案,并尽可能追求主要分子学缓解。
  • 首次复发时使用第一代TKI或无TKI提示预后较差,需积极优化挽救策略。
  • 第二次缓解后是否行异基因造血干细胞移植需权衡非复发死亡风险。

局限性

  • 回顾性研究,挽救治疗方案由治疗医生决定,存在选择偏倚。
  • 样本量有限,仅57例首次复发患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the advances in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with the introduction of tyrosine kinase inhibitors (TKIs), relapses remain challenging. We reviewed clinical data from adult patients with Ph + ALL who received frontline hyperCVAD chemotherapy with a TKI to determine their outcomes after first relapse. Patients with first morphological relapse after prior complete remission were evaluated for predictors of response and survival. For 57 of 233 (25%) patients, there was morphological relapse after a median of 15.9 months from first remission [range: 5.3-94]. The choice of salvage treatments was at the discretion of the treating physician. So, 43 (75%) patients received a TKI in combination with their salvage treatment. Second remission was achieved in 41 of 49 (84%) evaluable patients. Median relapse free survival (RFS) was 10.5 months [range, 0.2-81]. The 1-year and 2-year overall survival (OS) were 41% and 20% respectively. On multivariate analysis, only elevated LDH (units/L), the use of first-generation or no TKI at the time of first relapse and the achievement of a major molecular response (MMR) had a significant effect on OS (HR: 2.82, 95% CI:1.11-7.16, P = .029; HR = 2.39, 95% CI: 1.07,5.39, P = .034; HR = 0.39, 95% CI: 0.16-0.94, P = .03, respectively). Whereas, only achievement of MMR was significantly prognostic for RFS with a HR of 0.48 (95% CI: 0.23-0.98, P = .04). The OS and RFS were comparable between recipients and non-recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT) at second remission, due to a higher non-relapse mortality (53%) seen in patients who underwent alloHSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Abou Dalle I, Kantarjian HM, Short NJ, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019. PMID: 31595534. doi:10.1002/ajh.25648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。